Economy

Swedish inflation
Double reduction can worry the stock market: "More horror scenario"

There is no inflationary pressure in the Swedish economy and the interest rate must fall quickly to avoid a deflationary scenario. That's what Cevian founder Christer Gardell says in SVT's first Economic Bureau of the season.

- I actually see nothing that speaks against a double reduction.

Former Riksbank Governor Lars Heikensten and Första APfonden's Kristin Magnusson Bernard do not believe that the Riksbank will strike with a 50 basis point reduction next week. This is because it would be counterproductive and perhaps even create anxiety.

Instead, they predict several 25-point reductions in the autumn and clear guidance from the central bank.

Danske Bank's equity strategist Molly Guggenheimer says in the program that a double reduction could alarm the stock market, because it sends a signal that something has changed significantly in the economy.

- A double reduction is more out of a horror scenario.

.....................................

Electricity prices
The pizza baker about the electricity price in Skåne: "Gets upset"

Since the electricity price shock a couple of years ago, the price differences between Sweden's four electricity areas have evened out. But there is still a significant difference between the southern and northern parts of the country, writes TV4 Nyheterna.

This summer, the price in the south has been at least twice as high as in the far north. Among other things, it upsets the Malmö-based pizza baker Hamid Tahvildar, who says that he gets both "upset and sad".

- Why do I have to pay such a high price when you are a small business owner?

Bengt Ekenstierna, former top manager at Eon, believes that it is time to abolish electricity areas and introduce a new price model.

.......................................

Mpox virus Global cases
Danish vaccine company gets a lift from mpox spread

After the World Health Organization WHO this week declared an international health emergency for the spread of the mpox virus, Denmark has once again found itself in the spotlight for its drug capabilities, writes Bloomberg.

Bavarian Nordic is one of the few companies with an approved vaccine for mpox and has surged close to 50 percent on the stock market in the past week. The company can thus join the ranks of noted Danish drug developers such as Novo Nordisk, Zealand and Gubra.

Above all, it is Novo's success in obesity treatment that has given a boost to the entire sector in Denmark and attracted both capital and competent labor. On the Danish large company index OMX25, four drug developers are now crowded, writes Bloomberg.

Zealand CEO Adam Steensberg says that the success is partly due to Denmark investing in health problems that exist right now, but also those that are predicted to come further down the line.